Precision Optics (POCI) Fundamentals 2026 — Revenue Analysis | SniperIQ
Precision Optics (POCI) is a US-listed Healthcare company in Medical - Instruments & Supplies with a market capitalization of
Precision Optics (POCI) is a US-listed Healthcare company in Medical - Instruments & Supplies with a market capitalization of
Precision Optics (POCI) has a market capitalization of approximately
Precision Optics's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 1.8x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
Precision Optics runs a net profit margin of -17.0%, a gross margin of 13.8%, and an operating margin of -16.4%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
Precision Optics reported revenue of
Precision Optics does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Precision Optics carries a debt-to-equity ratio of 0.21x and a current ratio of 2.10x, with a market beta of 0.32. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Precision Optics (POCI) the key facts are: market cap
Get Precision Optics's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.